Rising Tumor Incidence Rates Fueling Growth In The Pheochromocytoma Market Driving Market Acceleration in the Pheochromocytoma Industry, 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts

How Large Will the Pheochromocytoma Market Size By 2025?
The market size of pheochromocytoma has been on a steady upward trend over the past years. It is projected to increase from $3.03 billion in 2024 to $3.17 billion in 2025, exhibiting a Compound Annual Growth Rate (CAGR) of 4.7%. The significant growth observed in the previous period is due to factors like increased healthcare spending, higher diagnostic rates and awareness, advancements in genetic research, and supportive government policies.

How Big Is the Pheochromocytoma Market Size Expected to Grow by 2029?
The market size for pheochromocytoma is predicted to experience consistent expansion in the coming years. It is projected to reach $3.74 billion by 2029, with a compound annual growth rate (CAGR) of 4.2%. This growth over the forecast period is largely due to the increased demand for combination therapies, investments poured into pheochromocytoma research and development, the preference for minimally invasive treatments for pheochromocytoma, and notable initiatives in rare disease research. The forecast period is also expected to see a rise in the number of drugs undergoing clinical trials, improvements in diagnosis and treatment methods, growing proficiency in gene therapy, and advancements in medical imaging.

View the full report here:
https://www.thebusinessresearchcompany.com/report/pheochromocytoma-global-market-report

Which Key Market Drivers Powering Pheochromocytoma Market Expansion and Growth?
An upward trend in the incidence rate of tumours is predicted to catapult the progress of the pheochromocytoma market in the future. Tumours, aberrant cell growths, can either be benign (non-cancerous) or malignant (cancerous). The surge in the number of tumour and cancer cases necessitates an increase in medical awareness, precise diagnosis, and niche treatment plans to deal with desmoid pheochromocytoma effectively. Notably, come January 2023, the American Cancer Society, a non-profit organization advocating for cancer in the US, reported an escalation to 1,958,310 cancer cases during 2023, marking a 3.16% growth compared to 1,898,160 in 2021. Thus, the mounting incidence rate of tumours will spur the expansion of the pheochromocytoma market. Underlining the first driver of the Pheochromocytoma Market - the increasing acceleration of neuroendocrine diseases is foreseen to bolster the growth trajectory of the pheochromocytoma market in the near future. Neuroendocrine diseases impact the neuroendocrine system, an intricate nexus of nerve cells and glands that construct and modulate hormones. A swell in the prevalence of neuroendocrine diseases, inclusive of pheochromocytomas, can conceivably stimulate demand for specialised diagnostics, treatment methods, surgeries, drugs, and tailored patient support services exclusive to this ailment. Specifically, in March 2023, as per the American Society of Clinical Oncology (ASCO), a non-profit entity based in the US, the yearly incidence of neuroendocrine diseases like pheochromocytoma is estimated to lie between 2 and 8 instances per 1 million people, with roughly 15% of these instances turning out to be cancerous. Furthermore, the prospective 5-year relative survival rate for recurring or metastatic pheochromocytomas is expected to fall within 34% to 60%. Hence, the amplifying occurrences of neuroendocrine diseases will steer the advancement of the pheochromocytoma market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12909&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the Pheochromocytoma Market?
Leading firms in the pheochromocytoma market are engaging in clinical studies to evaluate novel therapies, treatment methods, and drugs for pheochromocytoma, thereby advancing the development of more precise and potent treatments and enhancing patient results. For example, in August 2022, Switzerland's pharmaceutical giant, Novartis AG, commenced the second phase of their multicenter study, with transparent protocols, to gauge the safety levels and dosimetry of Lutathera in adolescents who are between 12 to less than 18 years old who are diagnosed with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), and pheochromocytoma and paragangliomas (PPGL). The study uses a comprehensive open-label single-armed strategy, which includes an exploratory PPGL group to cover as many affected teens with PPGL as feasible.

What Are the Emerging Segments in the Pheochromocytoma Market?
The pheochromocytoma market covered in this report is segmented -

1) By Type: Adrenal Pheochromocytoma, Extra-Adrenal Pheochromocytoma
2) By Treatment: Medication, Surgery, Radionuclide Treatment, Other Treatments
3) By Diagnosis: Laboratory Tests, Imaging Tests, Genetic Testing
4) By End Users: Hospitals, Clinics, Research And Academic Institutes, Other End Users

Subsegments:
1) By Adrenal Pheochromocytoma: Unilateral Adrenal Pheochromocytoma, Bilateral Adrenal Pheochromocytoma
2) By Extra-Adrenal Pheochromocytoma: Paraganglioma, Paraganglioma, Paraganglioma

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=12909&type=smp

Who Are the Global Leaders in the Pheochromocytoma Market?
Major companies operating in the pheochromocytoma market are Pfizer Inc., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Abbott Laboratories, Takeda Pharmaceutical Company Limited, Merck KGaA, Baxter International Inc., Teva Pharmaceutical Company Limited, Mylan N.V., Bausch Health Companies Inc., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Apotex Inc., Sun Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC, Endo International PLC, Exelixis Inc., Lupin Limited, Lantheus Holdings Inc., Curium Pharma, ANI Pharmaceuticals Inc., Jubilant Cadista Pharmaceuticals Inc., WellSpring Pharmaceutical Corporation, HRA Pharma SE.

Which are the Top Profitable Regional Markets for the Pheochromocytoma Industry?
North America was the largest region in the pheochromocytoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in pheochromocytoma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12909

"This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work."

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.